drugset
drugset / Trial / NCT06021054

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

NCT06021054 ↗

Phase 3 Completed 188 enrolled Viridian Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).

Timeline

Start
2023-11-14
Primary completion
2024-11-04
Completion
2025-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Veligrotug Monoclonal antibody 10 mg/kg Intravenous

Indications

endocrine exophthalmos